Medical/Pharmaceuticals News & Press Release Distribution

ReviR Therapeutics Raises $30 Million Series A Financing to Advance its Proprietary Oral Genetic Medicines for Multiple CNS Disorders

BRISBANE, Calif., July 26, 2024 /PRNewswire/ -- ReviR Therapeutics, an AI-enabled biotechnology company focused on developing small molecule RNA modulators for neurogenetic diseases, announced today that it has successfully completed a$30 million Series A financing, bringing the total raised so f...

2024-07-26 21:00 3148

CStone Announces European Commission Approval of Sugemalimab (Cejemly®) as First-Line Treatment for Non-Small Cell Lung Cancer

* Sugemalimab becomes the world's first anti-PD-L1 monoclonal antibody (mAb) approved inEurope for first-line treatment of both squamous and non-squamous non-small cell lung cancer (NSCLC), also marking the first successful international approval of aChina domestic anti-PD-L1 mAb. * The Eur...

2024-07-26 20:16 9718

MGI and HKBU Collaborate on Advanced Sequencing Technology to Combat Doping in Sports

PARIS, July 26, 2024 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technologies that drive innovation in life science, today announced its collaboration with renowned geneticist, Professor Yannis Pitsiladis from Hong Kong Baptist University, on sports a...

2024-07-26 19:35 3515

HanAll Biopharma Reports Q2 2024 Financial Results and Provides Business Update

* HanAll reports strong financial performance with second quarter total revenue of31.6 billion KRW, driven by the strong sales from the key products. * HanAll expands collaboration with Turn Biotechnologies through an exclusive licensing agreement for Epigenetic Reprogramming of Aging (ERATM) ...

2024-07-26 19:00 4530

Sanyou Bio Congratulates Eluminex Biosciences and Foreseen Biotechnology on Major Breakthroughs in Innovative Drug Project

SHANGHAI, July 26, 2024 /PRNewswire/ -- On July 15, Eluminex Biosciences announced that their tri-specific fusion antibody drug, EB-105, has administered its first dose to a diabetic macular edema patient inthe United States. This clinical trial, known as LOTUS, is an open-label, multicenter, si...

2024-07-26 18:00 3859

Vantage Markets Reveals "The Future of HealthTech" in the Latest Episode of The Vantage View

PORT VILA, Vanuatu, July 26, 2024 /PRNewswire/ -- Leading multi-asset broker, Vantage Markets

2024-07-26 17:05 2403

Vantage Australia Explores HealthTech's Future in the Latest Episode of The Vantage View

SYDNEY, July 26, 2024 /PRNewswire/ -- Leading multi-asset broker, Vantage Markets

2024-07-26 17:05 3211

Vantage Australia Explores HealthTech's Future in the Latest Episode of The Vantage View

Harbour BioMed to Present the Latest Progress of the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China , July 25, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immuno...

2024-07-26 10:16 1790

Innovent and WeComput Announce Strategic Partnership to Advance AI-Driven Drug Discovery and Development

SAN FRANCISCO and SUZHOU, China, July 26, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ...

2024-07-26 09:33 2839

Neurophet to launch total solution for AD treatments 'Neurophet AQUA AD' at AAIC 2024

- Demonstrates Neurophet AQUA AD for AD treatments such as Leqembi and Kisunla - Introduces updated version of Neurophet SCALE PET with centiloid scale feature SEOUL, South Korea, July 25, 2024 /PRNewswire/ -- Neurophet, an artificial intelligence (AI) solution company for brain disease, announc...

2024-07-25 21:00 1959

Neurophet to launch total solution for AD treatments 'Neurophet AQUA AD' at AAIC 2024

Peijia Medical's Licensing Partner, JenaValve Technology, Inc., is Expected to be Acquired by Edwards Lifesciences

Peijia to maintain exclusive rights in Greater China to commercialize JenaValve's Trilogy Transcatheter Heart Valve (THV) System SUZHOU, China, July 25, 2024 /PRNewswire/ -- Peijia Medical Limited (Peijia, (9996.HK)), a leading Chinese domestic player in the high-growth transcatheter valve thera...

2024-07-25 20:30 1995

Ractigen Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to RAG-18 for the treatment of Duchenne Muscular Dystrophy

SUZHOU, China, July 25, 2024 /PRNewswire/ -- Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to RAG-18, one of the company's lead saRN...

2024-07-25 20:00 1859

IASO Bio Announces NMPA Approval of IND Application for IASO-782 for Treatment of New Indication -- Systemic Lupus Erythematosus (SLE)

SHANGHAI, NANJING, China and SAN JOSE, Calif. , July 25, 2024 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing innovative cell therapy and antibody products, hereby announces thatthe investigation...

2024-07-25 17:46 2064

ObvioHealth announces strategic investment by Guardant Health to accelerate deployment of oncology clinical trials globally

SINGAPORE, July 25, 2024 /PRNewswire/ -- ObvioHealth , a global digital clinical trials company, announces a new strategic investment by Guardant Health, Inc., a leading precision oncology company offering liquid and tissue biopsy tests across the cancer research an...

2024-07-25 16:39 2600

Australasian College of Pharmacy and MedAdvisor Solutions Launch MedAdvisor software training for the Queensland Community Pharmacy Scope of Practice Pilot

Uplifting pharmacists' role in primary care and positioning pharmacies as essential care destinations in local communities CAMBERWELL, Australia, July 25, 2024 /PRNewswire/ -- MedAdvisor Solutions and the Australasian College of Pharmacy today announced the launch of the MedAdvisor software tra...

2024-07-25 05:00 2119

AI for Good: Insilico Medicine Hosts IMGAIA Product Launch Event

Announcing Sustainability Benchmarking Initiative and New Gen-AI Features of Pharma.AI Platform CAMBRIDGE, Mass., July 24, 2024 /PRNewswire/ -- Insilico Medicine ("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, recently hosts Insilico Medicine...

2024-07-24 21:00 1454

AI for Good: Insilico Medicine Hosts IMGAIA Product Launch Event

SoniVie announces advancements in its renal denervation program: REDUCED-1 pilot study results, radial access First-In-Human results, and FDA pivotal IDE approval of The THRIVE global study

SoniVie announces RDN pilot results, radial access FIH and FDA pivotal IDE approval, initiating the global THRIVE study in US,Europe and Israel TEL AVIV, Israel, July 24, 2024 /PRNewswire/ -- SoniVie , which has developed a novel proprietary Therapeutic Intra-Vascular Ultras...

2024-07-24 20:09 1553

SoniVie announces advancements in its renal denervation program: REDUCED-1 pilot study results, radial access First-In-Human results, and FDA pivotal IDE approval of The THRIVE global study

SoniVie announces RDN pilot results, radial access FIH and FDA pivotal IDE approval, initiating the global THRIVE study in US,Europe and Israel TEL AVIV, Israel, July 24, 2024 /PRNewswire/ -- SoniVie , which has developed a novel proprietary Therapeutic Intra-Vascular Ultras...

2024-07-24 19:46 1368

Corero Network Security Announces H1 Financial Results

Company posts 16% YoY growth with increases in ARR and bookings LONDON, July 24, 2024 /PRNewswire/ -- Corero Network Security (AIM: CNS) (OTCQB: DDOSF), the distributed denial of service (DDoS) protection specialists, today announced its financial results for the first half of 2024. The company ...

2024-07-24 19:00 3629

Corero Network Security Announces H1 Financial Results

Company posts 16% YoY growth with increases in ARR and bookings LONDON, July 24, 2024 /PRNewswire/ -- Corero Network Security (AIM: CNS) (OTCQB: DDOSF), the distributed denial of service (DDoS) protection specialists, today announced its financial results for the first half of 2024. The company ...

2024-07-24 19:00 3914